Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Payables (2016 - 2025)

Assembly Biosciences has reported Payables over the past 11 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Payables at $1.2 million for Q4 2025, up 100.17% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 100.17% YoY), and the annual figure for FY2025 was $1.2 million, up 100.17%.
  • Payables for Q4 2025 was $1.2 million at Assembly Biosciences, down from $1.7 million in the prior quarter.
  • Over the last five years, Payables for ASMB hit a ceiling of $3.6 million in Q1 2021 and a floor of $461000.0 in Q4 2023.
  • Median Payables over the past 5 years was $1.3 million (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Payables: tumbled 81.51% in 2023 and later soared 100.17% in 2025.
  • Assembly Biosciences' Payables stood at $2.7 million in 2021, then dropped by 6.24% to $2.5 million in 2022, then tumbled by 81.51% to $461000.0 in 2023, then grew by 26.9% to $585000.0 in 2024, then soared by 100.17% to $1.2 million in 2025.
  • The last three reported values for Payables were $1.2 million (Q4 2025), $1.7 million (Q3 2025), and $743000.0 (Q2 2025) per Business Quant data.